21 May 2013
Keywords: UCB, Financial results, Nine months 2012. Olokizumab, Licensing opportunity
Article | 29 October 2012
Belgium’s largest pharma company, UCB (UCB: BR), has reported interim results for the first nine months of 2012, in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 October 2012
© 2013 thepharmaletter.com